EN
Home/Start here/A few pounds, or before an event
Reading path3 guides, in order

I want to lose a few pounds before an event. Should I try a GLP-1?

An honest answer for anyone eyeing a weight-loss shot before a wedding, a vacation or a big day.

GLP Guidebook teamUpdated Oct 12, 20263 min read12 sourcesWritten from published sources
The short answer

Probably not. In the US, GLP-1 medicines are FDA-approved for type 2 diabetes, and for obesity or overweight with a related health problem, not for a few pounds. They take months to reach full dose, often upset the stomach, and the weight usually returns when you stop. Cheap online versions are often compounded, not FDA-approved. There are better ways to feel good on the day.

Read this page first. It covers why these medicines aren't meant for a few pounds, what happens after, fakes and compounded versions, and what works instead. At the end, three guides take you further, in order.
On this page
  1. Why it isn't meant for this
  2. Would it work in time?
  3. After the event
  4. Fakes and compounded versions
  5. What works instead
  6. What to read next
  7. Sources

Why isn't it meant for this?

These medicines treat a disease. They aren't meant for fine-tuning your weight.

Wanting to look and feel your best on a big day is completely normal. But the FDA approved these medicines for people with obesity, or overweight with a weight-related condition, alongside diet and activity changes.1,2

Here are the lines that matter in the US:

  • The label. Wegovy, Zepbound and Foundayo are approved for weight management in adults with a BMI (body mass index, your weight compared with your height) of 30 or more, or 27 to under 30 with at least one weight-related health problem, such as high blood pressure.1,2
  • The CDC's healthy range. The CDC counts a BMI of 18.5 to under 25 as healthy, and overweight from 25.3
  • Insurance. Plans that cover these medicines for weight usually require prior authorization, and Medicare can't cover them for weight loss alone.4,11
  • Ozempic. It is FDA-approved for type 2 diabetes, not for weight loss.10

So if you're in the healthy range, or just above it, these medicines aren't approved for you.

Would it even work in time?

Not really. The dose goes up slowly, over about 4 months.

Wegovy starts at 0.25 mg and steps up every 4 weeks. It reaches the usual dose of 2.4 mg after 16 weeks.1

Nausea and diarrhea were the most common side effects in STEP 1, the main semaglutide weight trial. People there got either the medicine or a dummy injection with no medicine in it. More people stopped because of stomach effects on the medicine.5

Out of every 100 people, how many stopped because of stomach effects:

STEP 1Semaglutide 2.4 mg (Wegovy), weekly

1,961 adults with obesity or overweight and no diabetes, 68 weeks.5

Semaglutide4.5 in 100
Dummy injection0.8 in 100

Bars are drawn on a scale up to 10 in 100.

Not ideal in the weeks before a celebration.

What happens after the event?

The weight usually comes back once you stop.

A year after stopping semaglutide, people followed up from STEP 1 had regained about two-thirds of the weight they lost.6 Most of their gains in blood pressure, sugar and cholesterol faded too.6

What about fakes and compounded versions?

Cheap or no-questions-asked offers carry real risks.

  • The WHO has found falsified Ozempic in Brazil, the UK and the US. Fakes may be missing the medicine, or contain a different one, such as insulin.12
  • The FDA has warned about counterfeit Ozempic in the US drug supply chain, most recently in December 2025.7
  • Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA has warned sellers of "research use only" products.8
Get help now. If you've injected a product of unknown origin and feel shaky, confused or faint, call 911. For advice on a possible overdose, call Poison Control on 1-800-222-1222.11

So what works instead?

A plan built around food and movement, started as early as you can.

The WHO says medicines alone won't solve weight problems. Healthy eating and physical activity remain the base of treatment.9 Guide 3: Your options sets out what the evidence says about each option.

And if your weight is affecting your health, that's a different conversation. Guide 1: Weight and health helps you check where you stand.

Your optionsConsidering it for weightStopping

What to read next, in order

These three guides go deeper. Each one ends with a link to the next, so you can read them one after another.

  1. 1Should I consider a GLP-1? And when not toGuide 4 of 9DecideThe section on losing a few pounds: who these medicines are for, and who they're not for.
  2. 2Your options, and where medicines fitGuide 3 of 9DecideFood, activity and other options, with what the evidence says about each.
  3. 3Stopping and the long termGuide 9 of 9Live with itWhat happens to weight, and to your body, when people stop.
Was this page easy to understand?

Sources

  1. Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026. Sections 1, 2.2, 5.2, 5.3, 5.5, 8.3. PDF
  2. Eli Lilly. Zepbound (tirzepatide) US prescribing information, revised August 2026, and Foundayo (orforglipron) US prescribing information, revised July 2026: section 1 (indications and BMI criteria). Zepbound · Foundayo
  3. CDC. Adult BMI categories. Page reviewed March 19, 2024. cdc.gov
  4. KFF. 2025 Employer Health Benefits Survey (GLP-1 coverage for weight loss typically subject to prior authorization). kff.org
  5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021;384:989–1002. 1,961 adults without diabetes, 68 weeks. DOI
  6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–1564. 327 people followed for a year after stopping. DOI
  7. FDA. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in US drug supply chain (December 21, 2023, April 14, 2025, December 5, 2025). fda.gov
  8. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
  9. World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. December 1, 2025. who.int
  10. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information and Medication Guide, revised May 2026. Sections 1, 4, 5. PDF
  11. KFF. Nearly four million Medicare beneficiaries met the eligibility criteria in 2023 for the Medicare GLP-1 Bridge (statutory prohibition on Medicare coverage of drugs used for weight loss). June 29, 2026. kff.org. America's Poison Centers. Poison Control: 1-800-222-1222. poison.org
  12. World Health Organization. WHO issues warning on falsified medicines used for diabetes treatment and weight loss. June 20, 2024. who.int

Last checked Oct 12, 2026 · Next review due Jan 2027

How this page was made. Written by the GLP Guidebook team from the sources above: FDA labels and notices, published trials, CDC and WHO guidance, and KFF research. It's general information, not medical advice. Talk to a doctor or another qualified prescriber before starting, stopping or changing any medicine. In an emergency, call 911. How we write